Author Archives: sivanew

Siva’s Targeted Hyperthermia™ Program Accepted by the Nanotechnology Characterization Laboratory

AUSTIN, TEXAS, August 29, 2016 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has been accepted has been accepted for characterization by the Nanotechnology Characterization Laboratory (NCL) in Frederick, Maryland. The NCL is a national resource which facilitates the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical NCL logoinfrastructure and characterization services, the NCL accelerates the transition of nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

Continue reading